PD-L2 inhib 
Welcome,         Profile    Billing    Logout  
 24 Companies  11 Products   11 Products   8 Diseases   150 Trials   1842 News 
216 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ezabenlimab (BI 754091) / Boehringer Ingelheim
NCT06370871: Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Withdrawn
3
263
NA
Brigimadlin, BI 907828, Ezabenlimab, BI 754091, Gemcitabine, Docetaxel
Boehringer Ingelheim
Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)
07/26
10/28
2018-002344-81: Platform trial evaluating safety and efficacy of BI 754091 anti- PD-1 based combination therapies in PD-(L)1 naïve and PD- (L)1 pretreated patient populations with advanced/metastatic solid tumours

Not yet recruiting
2
260
Europe
BI 754091, BI 754111, BI 836880, BI 754091, BI 754111, BI 836880, Solution for infusion
Boehringer Ingelheim Limited, Boehringer Ingelheim
Advanced/metastatic solid tumours, Advanced solid tumours, Diseases [C] - Cancer [C04]
 
 
2020-006046-40: Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by hypofractionated radiotherapy in patients with stage III squamous cell anal carcinoma. A phase II study. Ezabenlimab (BI 754091) et mDCF (docétaxel, cisplatine et 5-fluorouracile) suivis d'une radiothérapie hypofractionnée chez les patients atteints d'un carcinome anal épidermoïde de stade III. Une étude de phase II.

Not yet recruiting
2
55
Europe
Ezabenlimab, Docetaxel, Cisplatine, 5-Fluorouracile, BI 754091, , Concentrate for solution for infusion, DOCETAXEL ACCORD, CISPLATINE MYLAN, FLUOROURACILE ACCORD
CHU de Besançon, BOEHRINGER
cancer du canal anal de stade III cancer du canal anal de stade III, cancer du canal anal de stade III cancer du canal anal de stade III
 
 
BEAR, NCT04839471: BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma ( Study)

Completed
2
49
RoW
BI-754091 plus afatinib
National Health Research Institutes, Taiwan, Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
07/23
06/24
NCT03697304 / 2018-002344-81: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Completed
2
212
Europe, Canada, US
BI 754091, ezabenlimab, BI 754111, BI 836880
Boehringer Ingelheim, Boehringer Ingelheim
Neoplasm Metastasis
12/24
12/24
INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.

Active, not recruiting
2
55
Europe
Blood sample collection, Biopsy
Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim
Squamous Cell Carcinoma of the Anus Stage III
11/24
07/26
EMPIRE, NCT06084689: Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

Not yet recruiting
2
120
Europe
Ezabenlimab + BI907828
Institut Bergonié, Boehringer Ingelheim
Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Biliary Tract Cancer
07/26
01/27
NCT05879978: A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Active, not recruiting
1/2
45
Europe, Japan
Obrixtamig, BI 764532, Ezabenlimab
Boehringer Ingelheim
Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms
09/25
09/25
NCT02952248: A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Completed
1
112
Europe, Canada, US
BI 754091
Boehringer Ingelheim
Neoplasms
04/21
08/23
NCT04147234: A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Completed
1
42
Europe, US
BI 1387446 50 μg, BI 754091, Ezabenlimab, BI 1387446 100 μg, BI 1387446 200 μg, BI 1387446 400 μg
Boehringer Ingelheim
Neoplasms
11/22
03/24
NCT03156114: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Completed
1
172
Europe, Canada, US
BI 754111, BI 754091
Boehringer Ingelheim
Neoplasms, Carcinoma, Non-Small-Cell Lung
03/23
06/23
NCT03990233: A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Checkmark From trial in combination with BI 754091 for solid tumors
Jun 2021 - Jun 2021: From trial in combination with BI 754091 for solid tumors
Completed
1
100
Europe
BI 765063, OSE-172, BI 754091
OSE Immunotherapeutics, Boehringer Ingelheim
Solid Tumor, Adult
04/23
04/25
NCT04138823: A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)

Completed
1
12
Japan
BI 891065
Boehringer Ingelheim
Neoplasm
05/23
05/23
NCT03433898: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

Completed
1
146
Japan, RoW
BI 754091, BI 754111
Boehringer Ingelheim
Neoplasms
07/23
07/23
CAR2BRAIN, NCT03383978: Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Active, not recruiting
1
42
Europe
NK-92/5.28.z, Ezabenlimab
Johann Wolfgang Goethe University Hospital, DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH, Georg-Speyer-Haus, LOEWE Center Frankfurt Cancer Institute, German Cancer Research Center
Glioblastoma
12/25
06/26
NCT05446129: A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

Terminated
1
2
US
Ezabenlimab, BI 765063, Pembrolizumab
Boehringer Ingelheim
Colorectal Cancer
08/23
11/23
NCT04752215: A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

Completed
1
67
Canada, US
BI 765049, ezabenlimab
Boehringer Ingelheim
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
11/24
11/24
NCT05068102: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Recruiting
1
13
Europe
BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063, BI 770371, [89Zr]Zr- BI 770371
Boehringer Ingelheim
Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
10/25
12/25
KISIMA-01, NCT04046445: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Active, not recruiting
1
96
Europe, US
ATP128, BI 754091, Ezabenlimab, VSV-GP128
Amal Therapeutics, Boehringer Ingelheim
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
05/25
08/25
NCT03468426: A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Completed
1
252
Europe, US, RoW
BI 836880, ezabenlimab, BI 754091
Boehringer Ingelheim
Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
07/24
09/24
NCT05249426: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Active, not recruiting
1
48
Europe, Japan, US, RoW
BI 765063, Ezabenlimab, BI 754091, BI 836880, Cetuximab, Investigator´s Choice Chemotherapy
Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma (HNSCC)
07/24
07/26
NCT03964233: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Active, not recruiting
1
119
Europe, Japan, US, RoW
BI 907828, Brigimadlin, ezabenlimab, BI 754091, BI 754111
Boehringer Ingelheim
Neoplasms
09/24
05/26
1480-0001, NCT05471856: A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Recruiting
1
66
Europe, Japan, US
BI 1703880, Ezabenlimab, BI 754091
Boehringer Ingelheim
Solid Tumors
09/28
09/28
NCT05327946: A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Active, not recruiting
1
36
Canada, Japan, US
BI 770371, ezabenlimab
Boehringer Ingelheim
Solid Tumors
07/24
09/26
NCT04958239: A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Recruiting
1
160
Europe, Japan, US, RoW
BI 765179, Ezabenlimab, Pembrolizumab
Boehringer Ingelheim
Neoplasms
01/27
11/28
1456-0001 study, NCT05155332: A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Recruiting
1
190
Europe, US, RoW
BI 1831169, anti-PD-1 antibody
Boehringer Ingelheim
Solid Tumors
12/27
10/28
NCT06091930: A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Recruiting
1
70
Japan, RoW
BI 765049, Ezabenlimab, BI 754091
Boehringer Ingelheim
Gastrointestinal Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Cancer, Liver Cancer
11/26
02/27
KISIMA-02, NCT05846516: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC

Recruiting
1
85
Europe, US
VSV-GP154, ATP150, ATP152, Ezabenlimab
Amal Therapeutics, Boehringer Ingelheim
Pancreatic Ductal Adenocarcinoma
12/26
03/27
cetrelimab (JNJ-63723283) / J&J
2020-004506-64: A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Ongoing
3
1050
Europe
TAR-200, Cetrelimab, Vesiculture, JNJ-17000139, JNJ-63723283, Tablet, Powder for solution for infusion, Powder for bladder irrigation, Vesiculture, powder for bladder irrigation
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & development LLC, Janssen Research & Development LLC, Janssen-Cilag SpA, Janssen-cilag international NV
BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer, Bladder cancer, Diseases [C] - Cancer [C04]
 
 
SunRISe-2, NCT04658862 / 2020-002620-36: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Active, not recruiting
3
518
Europe, Canada, Japan, US, RoW
Cetrelimab, JNJ-63723283, TAR-200, JNJ-17000139, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
12/26
12/28
SunRISe-3, NCT05714202 / 2020-004506-64: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Active, not recruiting
3
1135
Europe, Canada, Japan, US, RoW
TAR-200, JNJ-17000139, Cetrelimab, JNJ-63723283, BCG Vesiculture
Janssen Research & Development, LLC, Janssen Research & development LLC, Janssen Research & Development LLC, Janssen-Cilag SpA, Janssen-cilag international NV
Bladder Cancer
09/29
09/29
2020-005565-13: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy Estudio de fase 2, multicéntrico, aleatorizado y abierto, de TAR-200 en combinación con cetrelimab y monoterapia con cetrelimab en participantes con carcinoma urotelial de vejiga músculo-invasivo que se vayan a tratar con cistectomía radical y no sean elegibles o rechacen recibir tratamiento con quimioterapia neoadyuvante basada en platino

Ongoing
2
160
Europe
TAR-200, Cetrelimab, JNJ-17000139, JNJ-63723283, Tablet, Lyophilisate for solution for infusion
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development LLC
Muscle-Invasive Urothelial Carcinoma of the Bladder Carcinoma urotelial de vejiga músculo-invasivo, Bladder cancer Cáncer de vejiga, Diseases [C] - Cancer [C04]
 
 
2022-002586-15: Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations and are ineligible for receiving cisplatin treatment Erdafitinib (ERDA) solo o en combinación con cetrelimab (CET) como tratamiento neoadyuvante (antes de la cirugía) en sujetos con cáncer de vejiga músculo-invasivo cuyos tumores expresan alteraciones del gen FGFR y no son elegibles para recibir tratamiento con cisplatino

Not yet recruiting
2
90
Europe
Cetrelimab, Erdafitinib, JNJ-63723283, JNJ-42756493, Solution for infusion, Tablet, Balversa
Spanish Oncology Genito Urinary Group (SOGUG), Spanish Oncology Genitourinary Group (SOGUG), Janssen Pharmaceutica NV
Muscle-invasive bladder cancer (MIBC) Cáncer de vejiga con invasión muscular, Bladder cancer that spreads beyond the inner lining of the bladder and into the muscle layer Cáncer de vejiga que se propaga al musculo grueso, Diseases [C] - Cancer [C04]
 
 
SOGUG-NEOWIN, NCT06511648 / 2022-002586-15: Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Recruiting
2
90
Europe
Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination
Spanish Oncology Genito-Urinary Group, Janssen-Cilag Ltd., Pivotal S.L.
Muscle-invasive Bladder Cancer
03/26
03/29
SunRISe-4, NCT04919512 / 2020-005565-13: A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruiting
2
163
Europe, US, RoW
TAR-200, JNJ-17000139, Cetrelimab, JNJ-63723283
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
01/25
03/27
NCT04926181: Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Terminated
2
2
US
Apalutamide, Erleada, Androgen Receptor Inhibitorsv(ARI), Apalutamide Oral Tablet, Cetrelimab, JNJ-63723283, Anti-PD-1 antibody cetrelimab (JNJ-63723283), CET
Rahul Aggarwal, Janssen Scientific Affairs, LLC
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
03/24
03/24
NCT06534190: CD8 PET Imaging in Metastatic Solid Tumours

Recruiting
2
30
Europe
89Zr-Df-crefmirlimab PET scan, Nivolumab, Cetrelimab, zirconium Zr 89 crefmirlimab berdoxam, Zr-89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C
University Medical Center Groningen
Locally Advanced Solid Tumor
11/28
11/28
C3NIRA, NCT04592237: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Active, not recruiting
2
120
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cetrelimab, JNJ 63723283, JNJ-63723283, JNJ63723283, WHO 10757, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center, Janssen Pharmaceutica
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
12/25
12/25
SunRISe-1, NCT04640623 / 2020-002646-16: A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Active, not recruiting
2
220
Europe, Canada, Japan, US, RoW
TAR-200, JNJ-17000139, Gemcitabine-Releasing Intravesical System, Cetrelimab, JNJ-63723283
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
11/26
07/27
QUEST, NCT03431350 / 2017-003552-23: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
1/2
136
Europe, Canada, US, RoW
Niraparib 200 mg, Cetrelimab 240 mg, JNJ-63723283, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg
Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
08/21
12/25
NORSE, NCT03473743 / 2017-001980-19: A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Checkmark Presenation of data from NORSE trial in combination with cetrelimab for 2L metastatic urothelial carcinoma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from NORSE trial in combination with cetrelimab for 2L metastatic urothelial carcinoma at ESMO 2021
Checkmark Presenation of data from NORSE trial in combination with BALVERSA for 2L metastatic urothelial carcinoma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from NORSE trial in combination with BALVERSA for 2L metastatic urothelial carcinoma at ESMO 2021
Active, not recruiting
1/2
125
Europe, US, RoW
Erdafitinib, JNJ-42756493, Cetrelimab, JNJ-63723283, Cisplatin, Carboplatin
Janssen Research & Development, LLC
Urothelial Carcinoma
09/22
12/25
NCT02908906 / 2016-002017-22: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Active, not recruiting
1/2
413
Europe, US, RoW
JNJ-63723283, Cetrelimab
Janssen Research & Development, LLC
Neoplasms
11/23
10/25
PolyDamas, NCT05908734: A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

Recruiting
1/2
75
Europe, US, RoW
Cetrelimab, JNJ-63723283, Amivantamab, JNJ-61186372
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
06/25
09/26
NCT05242445: A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Completed
1
11
Europe
Cetrelimab, JNJ-63723283, Placebo
Janssen Research & Development, LLC
Hepatitis B, Chronic
05/23
05/23
NCT06311578: A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Recruiting
1
96
Europe, US
JNJ-87704916, Cetrelimab, JNJ-63723283
Johnson & Johnson Enterprise Innovation Inc.
Advanced Solid Tumors
11/28
11/33
NCT05818683: A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Recruiting
1
176
Europe, US, RoW
JNJ-78278343, Cetrelimab, JNJ-63723283, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP)
Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Neoplasms
06/26
09/27
ANK-101-004, NCT07027514: A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Not yet recruiting
1
60
NA
tolododekin alfa, Cetrelimab
Ankyra Therapeutics, Inc
Non Small Cell Lung Cancer
06/27
12/28
NCT06116786: A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Recruiting
1
126
Europe, US, RoW
JNJ-86974680, Cetrelimab, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc.
Carcinoma, Non-small-Cell Lung
04/27
06/29
Zynyz (retifanlimab-dlwr) / Incyte
POD1UM-304, NCT04205812 / 2019-003372-39: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Active, not recruiting
3
583
Europe, US, RoW
Retifanlimab, INCMGA00012, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel
Incyte Corporation, Zai Lab (Shanghai) Co., Ltd.
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
12/23
08/26
POD1UM-303, NCT04472429 / 2020-000826-24: Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (/InterAACT 2).

Hourglass Dec 2024 - Dec 2024 : sBLA submission for SCAC
Active, not recruiting
3
308
Europe, Japan, US, RoW
carboplatin, paclitaxel, retifanlimab, INCMGA00012
Incyte Corporation
Squamous Cell Carcinoma of the Anal Canal
04/24
03/26
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
01/26
06/26
2019-004699-21: Study of Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in HER2-Positive Gastric or Gastroesophageal Junction Cancer

Not yet recruiting
2/3
860
Europe, RoW
Margetuximab, INCMGA00012, MGD013, Trastuzumab, MGAH22, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Herceptin
MacroGenics, Inc., MACROGENICS, INC., MacroGenics, Inc., Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator),  Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator), Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator)
Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer, Gastric Cancer or Gastroesophageal Junction Cancer, Diseases [C] - Cancer [C04]
 
 
MAHOGANY, NCT04082364 / 2019-004699-21: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Completed
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
03/25
2021-001181-38: Study on the treatment of patients with gastroesophageal cancer with chemotherapy and immunotherapy based on a non-functioning DNA mismatch repair mechanism in the tumour cells Onderzoek naar de behandeling van patiënten met maag-/slokdarmkanker met chemotherapie en immunotherapie op basis van een niet werkend DNA mismatch herstel mechanisme in de tumorcellen

Not yet recruiting
2
25
Europe
Retifanlimab, INCMGA00012, Solution for infusion
Academic Medical Center, Incyte
Gastroesophageal cancer Oesophagus- en maagcarcinoom, Gastroesophageal cancer Slokdarm- en maagkanker, Diseases [C] - Cancer [C04]
 
 
2020-002244-23: An Open-Label, Randomized, Phase 2, Study of Various Therapies for Participants With Muscle-Invasive bladder cancer who are not eligible for Cisplatin or Refuse Cisplatin Therapy and are having bladder removal (Optimus) Studio generale in aperto, randomizzato, di fase 2 per valutare varie terapie per partecipanti con carcinoma muscolo-invasivo della vescica che sono non idonei al cisplatino o rifiutano la terapia con cisplatino e si sottopongono rimozione della vescica (Optimus)

Not yet recruiting
2
45
Europe
Epacadostat, Retifanlimab, [INCB024360], [INCMGA00012], Tablet, Solution for infusion
INCYTE CORPORATION, Incyte Corporation
Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy Carcinoma uroteliale muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e si sottopone a cistectomia radicale, Muscle-Invasive Bladder cancer Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and having bladder removal Carcinoma muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e con rimozione della vescica, Diseases [C] - Cancer [C04]
 
 
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II.

Not yet recruiting
2
66
Europe
Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide)
Institut Bergonié, Incyte Biosciences International Sarl
retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04]
 
 
2018-002070-51: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Not yet recruiting
2
81
Europe, RoW
INCMGA00012, Solution for infusion
Incyte Corporation, Incyte Corporation
Squamous Carcinoma of the Anal Canal, Squamous Carcinoma of the Anal Canal, Diseases [C] - Cancer [C04]
 
 
POD1UM-201, NCT03599713 / 2018-001627-39: A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma

Checkmark Data from PODIUM-201 trial for metastatic merkel cell carcinoma at SITC 2021
Nov 2021 - Nov 2021: Data from PODIUM-201 trial for metastatic merkel cell carcinoma at SITC 2021
Checkmark Data from POD1UM-201 trial in Merkel cell carcinoma at ESMO 2020
Sep 2020 - Sep 2020: Data from POD1UM-201 trial in Merkel cell carcinoma at ESMO 2020
Completed
2
107
Europe, Canada, US, RoW
Retifanlimab, MGA012, INCMGA00012
Incyte Corporation
Metastatic Merkel Cell Carcinoma
01/22
06/24
2021-005775-39: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Estudio an fase II, aleatorizado, doble ciego y multicéntrico de retifanlimab en combinación con INCAGN02385 e INCAGN02390 como tratamiento de primera línea en participantes con carcinoma escamoso de cabeza y cuello metastásico/recidivante .

Ongoing
2
162
Europe
Retifanlimab, INCMGA00012, INCAGN02385, INCAGN0290, Solution for infusion
Incyte Biosciences International Sarl, Incyte Biosciences International Sarl
In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN. En participantes con PD-L1 positivo y terapia sistémica R/M SCCHN sin tratamiento previo., In participants with biomarker positive and untreated advanced head and neck cancer En participantes con biomarcadores positivos y con cancer de cabeza y cuello avanzado no tratado., Diseases [C] - Cancer [C04]
 
 
NCT04225039: Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

Active, not recruiting
2
39
US
INCMGA00012, PD-1 inhibitor, PD1, INCAGN01876, Anti-GITR agonist, GITR, SRS, stereotactic radiosurgery, Brain surgery
University of Pennsylvania, Incyte Corporation
Glioblastoma
09/22
06/25
2022-000601-27: Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surgery in patients with operable Merkel cell carcinoma Studio volto a testare l’attività di un ciclo di chemio-immunoterapia con retifanlimab associato a platino-etoposide e seguito da chirurgia nei pazienti con carcinoma a cellule di Merkel operabile

Not yet recruiting
2
36
Europe
RETIFANLIMAB, CISPLATINO, carboplatino, etoposide, [INCMGA00012], [CISPLATINO], [carboplatino], [etoposide], Concentrate for solution for infusion
Fondazione GONO, Incyte Biosciences International, Fondazione GONO Onlus
The disease under clinical investigation is represented by resectable Merkel Cell Carcinoma (MCC), stage IIA-III (according to the AJCC staging system 8th edition). The study will include patients with a disease amenable for radical surgery as defined by local or institutional surgical practices, based on multidisciplinary team assessment La malattia oggetto di studio clinico è rappresentata dal tumore a cellule di Merkel (MCC) resecabile, stadiato clinicamente secondo il sistema di stadiazione AJCC, ottava edizione, come stadio IIA-III. Il protocollo arruolerà pazienti candidabili a trattamento chirurgico radicale secondo quanto definito dalla pratica clinica locale ed istituzionale, in seguito a valutazione in ambito multidisciplinare, Merkel cell carcinoma without metastases in other organs and surgically resectable Carcinoma a cellule di Merkel senza metastasi in altri organi e asportabile chirurgicamente, Diseases [C] - Cancer [C04]
 
 
ORPHEUS, NCT04231981 / 2019-001172-11: Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma

Completed
2
18
Europe
Retifanlimab, INCMGA0012
MedSIR, Incyte Biosciences International Sàrl
Penile Cancer
02/22
08/22
IRENE, NCT04445844: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, Study

Checkmark Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Dec 2021 - Dec 2021: Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Active, not recruiting
2
25
US
Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012
Mridula George, MD, Incyte Corporation, Oncolytics Biotech, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
06/25
06/25
NCT04949191 / 2021-002207-36: The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Terminated
2
10
Europe, Japan, US
Pemigatinib, INCB054828, Retifanlimab, INCMGA0012, Pembrolizumab
Incyte Corporation, Incyte Corporation
Advanced Malignancies
04/24
04/24
RHAPSODY, NCT04494009: PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy

Active, not recruiting
2
110
RoW
INCMGA00012
Asan Medical Center
Esophageal Cancer
12/25
12/26
NCT03532295: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Hourglass Jan 2019 - Jan 2019 : P2 trial in recurrent gliomas
Active, not recruiting
2
51
US
Epacadostat, Bevacizumab, Avastin, Radiation therapy, Peripheral blood draw, Retifanlimab, INCMGA00012
Washington University School of Medicine, Incyte Corporation
Glioma, Glioblastoma
07/24
04/26
NCT05359692: INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Withdrawn
2
47
US
INCAGN01876, retifanlimab
Incyte Biosciences International Sàrl
Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
04/24
01/25
Optimus, NCT04586244 / 2020-002244-23: An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Terminated
2
30
Europe, US
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Incyte Corporation, Incyte Corporation
Urothelial Carcinoma
01/24
01/24
NCT05287113: Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
2
176
Europe, Canada, US, RoW
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Incyte Biosciences International Sàrl
Head and Neck Cancer
03/25
06/25
PERELI, NCT06389799: A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma

Recruiting
2
33
Europe
Pemigatinib, Retifanlimab
Lund University Hospital
Dedifferentiated Liposarcoma
12/27
12/28
NCT06160206: Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recruiting
2
134
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
11/26
11/30
MERCURY, NCT05594290: Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery

Recruiting
2
36
Europe
Retifanlimab, Cisplatin, Etoposide
Gruppo Oncologico del Nord-Ovest
Merkel Cell Carcinoma
11/25
11/26
NCT04116073: INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Completed
2
25
US
INCMGA00012 (PD-1 antibody), MGA012
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI)
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
08/24
12/24
RiLEY, NCT05239182: 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Active, not recruiting
2
32
US
9-ING-41, Retifanlimab, INCMGA00012, Gemcitabine, Abraxane
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
12/24
06/25
TORNADO, NCT04968106: Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas

Recruiting
2
66
Europe
Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab
Institut Bergonié, Incyte Biosciences International Sàrl
Resectable Sarcoma
03/25
10/27
POD1UM-204, NCT04463771 / 2020-000496-20: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Active, not recruiting
2
206
Europe, US, RoW
retifanlimab, INCMGA00012, epacadostat, pemigatinib, INCAGN02385, INCAGN02390
Incyte Corporation, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Cancer
04/26
07/26
AuspiCiOus, NCT05177133: Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer

Recruiting
2
25
Europe
Capecitabine, Xeloda, Oxaliplatin, Oxaliplatin Accord, Retifanlimab, INCMGA00012
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Incyte Corporation
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
05/25
11/29
NCT04438824: Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Active, not recruiting
2
42
US
INCMGA00012, Palbociclib
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Well-differentiated/Dedifferentiated Liposarcoma
06/26
06/26
NCT05345002: All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Recruiting
2
55
US
Retifanlimab, All-trans retinoic acid
Stephen Bagley, MD, MSCE, Incyte Corporation, University of Pennsylvania
Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma
06/26
06/27
TRICK-MCC, NCT06056895: Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Active, not recruiting
2
12
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Tuparstobart, Anti-LAG-3 Monoclonal Antibody INCAGN02385, Anti-LAG3 Monoclonal Antibody INCAGN02385, INCAGN 02385, INCAGN 2385, INCAGN02385, INCAGN2385, Verzistobart, Anti-TIM-3 Monoclonal Antibody INCAGN02390, INCAGN 02390, INCAGN-02390, INCAGN02390
University of Washington, Incyte Corporation
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
01/27
04/27
CP-MGC018-01, NCT03729596 / 2018-003555-38: MGC018 With or Without MGA012 in Advanced Solid Tumors

Terminated
1/2
143
Europe, US, RoW
vobramitamab duocarmazine, MGC018
MacroGenics, MacroGenics, Inc.
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer
03/23
03/23
2018-003555-38: Study of MGC018 Alone and in Combination with MGA012 in Patients with Advanced Solid Tumors

Not yet recruiting
1/2
193
Europe
MGC018, MGA012 (INCMGA00012), NA, Concentrate for solution for infusion
MacroGenics, Inc., MacroGenics, Inc.
Advanced Solid Tumors, Advanced cancer disease, Diseases [C] - Cancer [C04]
 
 
NCT06149481: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Recruiting
1/2
60
US
Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682
National Cancer Institute (NCI)
Metastatic Colorectal Cancer
10/25
10/28
NCT06320405: Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Recruiting
1/2
38
US
Axatilimab, Anti-M-CSFR Monoclonal Antibody SNDX-6352, SNDX 6352, SNDX-6352, SNDX6352, UCB6352, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
04/27
04/29
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Anticipated efficiency data in combination with Bria-IMT
Dec 2018 - Dec 2018: Anticipated efficiency data in combination with Bria-IMT
Checkmark Safety data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
11/25
11/28
SANTANA-225, NCT06939036: Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC ( )

Recruiting
1/2
50
US
225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
Ariceum Therapeutics GmbH
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
08/26
12/26
NCT06873789: A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Recruiting
1/2
322
US
INCB177054, Retifanlimab
Incyte Corporation
Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
10/28
10/28
NCT04370704: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Active, not recruiting
1/2
61
US, RoW
INCAGN02385, INCAGN02390, INCMGA00012.
Incyte Corporation
Melanoma
08/25
08/25
NCT04577014: Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Recruiting
1/2
98
US
Retifanlimab, INCMGA00012, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
09/26
09/26
NCT06959537: A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Not yet recruiting
1/2
24
US
Cyclophosphamide, Axatilimab (SNDX-6352), Retifanlimab
M.D. Anderson Cancer Center
Breast Cancer
01/27
01/29
NCT05455697: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Recruiting
1/2
35
US
Bone Marrow Biopsy, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cyclostine, Cytophosphane, Cytoxan, Fosfaseron, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, 14-Hydroxydaunomycin, 23214-92-8, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Prednisone, Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltra, Econosone, Lisacort, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Predicor, Predicorten, Prednicort, Prednilonga, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Retifanlimab, 2226345-85-1, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Tafasitamab, 1422527-84-1, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, 22-Oxovincaleukoblastine, 57-22-7, LEUROCRISTINE, VCR, Vincrystine, Bone Marrow Aspiration, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Fludeoxyglucose F-18, 105851-17-0, 18FDG, Positron Emission Tomography, Medical Imaging, PET Scan, Positron Emission Tomography Scan, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Biospecimen Collection, Biological Sample Collection, Polatuzumab Vedotin, Antibody-Drug Conjugate DCDS4501A, Polivy
University of Washington
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
01/27
07/27
INCMGA 0012-102, NCT03589651: INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Completed
1b
83
US
Retifanlimab, Epacadostat, INCB024360, INCMGA00012, INCB050465
Incyte Corporation
Unresectable or Metastatic Solid Tumors
11/22
11/22
NCT04799431: Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

Withdrawn
1
12
NA
Neoantigen Vaccine with Poly-ICLC adjuvant, Hiltonol® (Poly-ICLC), Retifanlimab, INCMGA00012; MGA012
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI)
Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
05/23
05/23
NCT03522142: A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Active, not recruiting
1
84
Europe, US
INCB081776, INCMGA00012, retifanlimab
Incyte Corporation
Advanced Solid Tumors
09/25
09/25
NCT04470024: Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Recruiting
1
56
US
INCAGN01876, INCMGA00012, DPV-001
Providence Health & Services
Cancer of the Head and Neck
12/25
12/27
NCT06179160: A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting
1
466
Europe, Canada, Japan, US, RoW
INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX
Incyte Corporation
Solid Tumors
01/27
01/27
NCT04580485: INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Completed
1
54
Europe, US
INCB106385, INCMGA00012
Incyte Corporation
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
01/24
01/24
NCT04989387: Study of INCA 0186 in Subjects With Advanced Solid Tumors

Completed
1
57
Europe, US
INCA00186, Retifanlimab, INCB106385
Incyte Corporation
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
09/24
09/24
POD1UM-101, NCT03059823: A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Checkmark Data from PODIUM-101 trial for endometrial cancer at SITC 2021
Nov 2021 - Nov 2021: Data from PODIUM-101 trial for endometrial cancer at SITC 2021
Checkmark First patient dosed in China for 2L MSI-H endometrial cancer
Nov 2020 - Nov 2020: First patient dosed in China for 2L MSI-H endometrial cancer
Checkmark Preliminary data from PODIUM-101 trial for endometrial cancer at SITC 2020
More
Completed
1
325
Europe, US, RoW
retifanlimab, INCMGA0012
Incyte Corporation
Locally Advanced Solid Tumors, Metastatic Solid Tumors
05/24
05/24
NCT06290622: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Withdrawn
1
18
NA
Retifanlimab, INCAGN02385, INCAGN02390
University of Alabama at Birmingham
Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular
06/26
01/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ezabenlimab (BI 754091) / Boehringer Ingelheim
NCT06370871: Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Withdrawn
3
263
NA
Brigimadlin, BI 907828, Ezabenlimab, BI 754091, Gemcitabine, Docetaxel
Boehringer Ingelheim
Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)
07/26
10/28
2018-002344-81: Platform trial evaluating safety and efficacy of BI 754091 anti- PD-1 based combination therapies in PD-(L)1 naïve and PD- (L)1 pretreated patient populations with advanced/metastatic solid tumours

Not yet recruiting
2
260
Europe
BI 754091, BI 754111, BI 836880, BI 754091, BI 754111, BI 836880, Solution for infusion
Boehringer Ingelheim Limited, Boehringer Ingelheim
Advanced/metastatic solid tumours, Advanced solid tumours, Diseases [C] - Cancer [C04]
 
 
2020-006046-40: Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by hypofractionated radiotherapy in patients with stage III squamous cell anal carcinoma. A phase II study. Ezabenlimab (BI 754091) et mDCF (docétaxel, cisplatine et 5-fluorouracile) suivis d'une radiothérapie hypofractionnée chez les patients atteints d'un carcinome anal épidermoïde de stade III. Une étude de phase II.

Not yet recruiting
2
55
Europe
Ezabenlimab, Docetaxel, Cisplatine, 5-Fluorouracile, BI 754091, , Concentrate for solution for infusion, DOCETAXEL ACCORD, CISPLATINE MYLAN, FLUOROURACILE ACCORD
CHU de Besançon, BOEHRINGER
cancer du canal anal de stade III cancer du canal anal de stade III, cancer du canal anal de stade III cancer du canal anal de stade III
 
 
BEAR, NCT04839471: BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma ( Study)

Completed
2
49
RoW
BI-754091 plus afatinib
National Health Research Institutes, Taiwan, Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
07/23
06/24
NCT03697304 / 2018-002344-81: Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Completed
2
212
Europe, Canada, US
BI 754091, ezabenlimab, BI 754111, BI 836880
Boehringer Ingelheim, Boehringer Ingelheim
Neoplasm Metastasis
12/24
12/24
INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.

Active, not recruiting
2
55
Europe
Blood sample collection, Biopsy
Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim
Squamous Cell Carcinoma of the Anus Stage III
11/24
07/26
EMPIRE, NCT06084689: Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

Not yet recruiting
2
120
Europe
Ezabenlimab + BI907828
Institut Bergonié, Boehringer Ingelheim
Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Biliary Tract Cancer
07/26
01/27
NCT05879978: A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Active, not recruiting
1/2
45
Europe, Japan
Obrixtamig, BI 764532, Ezabenlimab
Boehringer Ingelheim
Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms
09/25
09/25
NCT02952248: A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Completed
1
112
Europe, Canada, US
BI 754091
Boehringer Ingelheim
Neoplasms
04/21
08/23
NCT04147234: A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Completed
1
42
Europe, US
BI 1387446 50 μg, BI 754091, Ezabenlimab, BI 1387446 100 μg, BI 1387446 200 μg, BI 1387446 400 μg
Boehringer Ingelheim
Neoplasms
11/22
03/24
NCT03156114: This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Completed
1
172
Europe, Canada, US
BI 754111, BI 754091
Boehringer Ingelheim
Neoplasms, Carcinoma, Non-Small-Cell Lung
03/23
06/23
NCT03990233: A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Checkmark From trial in combination with BI 754091 for solid tumors
Jun 2021 - Jun 2021: From trial in combination with BI 754091 for solid tumors
Completed
1
100
Europe
BI 765063, OSE-172, BI 754091
OSE Immunotherapeutics, Boehringer Ingelheim
Solid Tumor, Adult
04/23
04/25
NCT04138823: A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)

Completed
1
12
Japan
BI 891065
Boehringer Ingelheim
Neoplasm
05/23
05/23
NCT03433898: This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

Completed
1
146
Japan, RoW
BI 754091, BI 754111
Boehringer Ingelheim
Neoplasms
07/23
07/23
CAR2BRAIN, NCT03383978: Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Active, not recruiting
1
42
Europe
NK-92/5.28.z, Ezabenlimab
Johann Wolfgang Goethe University Hospital, DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH, Georg-Speyer-Haus, LOEWE Center Frankfurt Cancer Institute, German Cancer Research Center
Glioblastoma
12/25
06/26
NCT05446129: A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

Terminated
1
2
US
Ezabenlimab, BI 765063, Pembrolizumab
Boehringer Ingelheim
Colorectal Cancer
08/23
11/23
NCT04752215: A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

Completed
1
67
Canada, US
BI 765049, ezabenlimab
Boehringer Ingelheim
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
11/24
11/24
NCT05068102: A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Recruiting
1
13
Europe
BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063, BI 770371, [89Zr]Zr- BI 770371
Boehringer Ingelheim
Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
10/25
12/25
KISIMA-01, NCT04046445: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Active, not recruiting
1
96
Europe, US
ATP128, BI 754091, Ezabenlimab, VSV-GP128
Amal Therapeutics, Boehringer Ingelheim
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
05/25
08/25
NCT03468426: A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Completed
1
252
Europe, US, RoW
BI 836880, ezabenlimab, BI 754091
Boehringer Ingelheim
Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
07/24
09/24
NCT05249426: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Active, not recruiting
1
48
Europe, Japan, US, RoW
BI 765063, Ezabenlimab, BI 754091, BI 836880, Cetuximab, Investigator´s Choice Chemotherapy
Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma (HNSCC)
07/24
07/26
NCT03964233: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Active, not recruiting
1
119
Europe, Japan, US, RoW
BI 907828, Brigimadlin, ezabenlimab, BI 754091, BI 754111
Boehringer Ingelheim
Neoplasms
09/24
05/26
1480-0001, NCT05471856: A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Recruiting
1
66
Europe, Japan, US
BI 1703880, Ezabenlimab, BI 754091
Boehringer Ingelheim
Solid Tumors
09/28
09/28
NCT05327946: A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Active, not recruiting
1
36
Canada, Japan, US
BI 770371, ezabenlimab
Boehringer Ingelheim
Solid Tumors
07/24
09/26
NCT04958239: A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Recruiting
1
160
Europe, Japan, US, RoW
BI 765179, Ezabenlimab, Pembrolizumab
Boehringer Ingelheim
Neoplasms
01/27
11/28
1456-0001 study, NCT05155332: A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Recruiting
1
190
Europe, US, RoW
BI 1831169, anti-PD-1 antibody
Boehringer Ingelheim
Solid Tumors
12/27
10/28
NCT06091930: A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Recruiting
1
70
Japan, RoW
BI 765049, Ezabenlimab, BI 754091
Boehringer Ingelheim
Gastrointestinal Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Cancer, Liver Cancer
11/26
02/27
KISIMA-02, NCT05846516: A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC

Recruiting
1
85
Europe, US
VSV-GP154, ATP150, ATP152, Ezabenlimab
Amal Therapeutics, Boehringer Ingelheim
Pancreatic Ductal Adenocarcinoma
12/26
03/27
cetrelimab (JNJ-63723283) / J&J
2020-004506-64: A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Ongoing
3
1050
Europe
TAR-200, Cetrelimab, Vesiculture, JNJ-17000139, JNJ-63723283, Tablet, Powder for solution for infusion, Powder for bladder irrigation, Vesiculture, powder for bladder irrigation
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & development LLC, Janssen Research & Development LLC, Janssen-Cilag SpA, Janssen-cilag international NV
BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer, Bladder cancer, Diseases [C] - Cancer [C04]
 
 
SunRISe-2, NCT04658862 / 2020-002620-36: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Active, not recruiting
3
518
Europe, Canada, Japan, US, RoW
Cetrelimab, JNJ-63723283, TAR-200, JNJ-17000139, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
12/26
12/28
SunRISe-3, NCT05714202 / 2020-004506-64: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Active, not recruiting
3
1135
Europe, Canada, Japan, US, RoW
TAR-200, JNJ-17000139, Cetrelimab, JNJ-63723283, BCG Vesiculture
Janssen Research & Development, LLC, Janssen Research & development LLC, Janssen Research & Development LLC, Janssen-Cilag SpA, Janssen-cilag international NV
Bladder Cancer
09/29
09/29
2020-005565-13: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy Estudio de fase 2, multicéntrico, aleatorizado y abierto, de TAR-200 en combinación con cetrelimab y monoterapia con cetrelimab en participantes con carcinoma urotelial de vejiga músculo-invasivo que se vayan a tratar con cistectomía radical y no sean elegibles o rechacen recibir tratamiento con quimioterapia neoadyuvante basada en platino

Ongoing
2
160
Europe
TAR-200, Cetrelimab, JNJ-17000139, JNJ-63723283, Tablet, Lyophilisate for solution for infusion
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development LLC
Muscle-Invasive Urothelial Carcinoma of the Bladder Carcinoma urotelial de vejiga músculo-invasivo, Bladder cancer Cáncer de vejiga, Diseases [C] - Cancer [C04]
 
 
2022-002586-15: Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations and are ineligible for receiving cisplatin treatment Erdafitinib (ERDA) solo o en combinación con cetrelimab (CET) como tratamiento neoadyuvante (antes de la cirugía) en sujetos con cáncer de vejiga músculo-invasivo cuyos tumores expresan alteraciones del gen FGFR y no son elegibles para recibir tratamiento con cisplatino

Not yet recruiting
2
90
Europe
Cetrelimab, Erdafitinib, JNJ-63723283, JNJ-42756493, Solution for infusion, Tablet, Balversa
Spanish Oncology Genito Urinary Group (SOGUG), Spanish Oncology Genitourinary Group (SOGUG), Janssen Pharmaceutica NV
Muscle-invasive bladder cancer (MIBC) Cáncer de vejiga con invasión muscular, Bladder cancer that spreads beyond the inner lining of the bladder and into the muscle layer Cáncer de vejiga que se propaga al musculo grueso, Diseases [C] - Cancer [C04]
 
 
SOGUG-NEOWIN, NCT06511648 / 2022-002586-15: Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Recruiting
2
90
Europe
Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination
Spanish Oncology Genito-Urinary Group, Janssen-Cilag Ltd., Pivotal S.L.
Muscle-invasive Bladder Cancer
03/26
03/29
SunRISe-4, NCT04919512 / 2020-005565-13: A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruiting
2
163
Europe, US, RoW
TAR-200, JNJ-17000139, Cetrelimab, JNJ-63723283
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
01/25
03/27
NCT04926181: Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Terminated
2
2
US
Apalutamide, Erleada, Androgen Receptor Inhibitorsv(ARI), Apalutamide Oral Tablet, Cetrelimab, JNJ-63723283, Anti-PD-1 antibody cetrelimab (JNJ-63723283), CET
Rahul Aggarwal, Janssen Scientific Affairs, LLC
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
03/24
03/24
NCT06534190: CD8 PET Imaging in Metastatic Solid Tumours

Recruiting
2
30
Europe
89Zr-Df-crefmirlimab PET scan, Nivolumab, Cetrelimab, zirconium Zr 89 crefmirlimab berdoxam, Zr-89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C
University Medical Center Groningen
Locally Advanced Solid Tumor
11/28
11/28
C3NIRA, NCT04592237: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Active, not recruiting
2
120
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cetrelimab, JNJ 63723283, JNJ-63723283, JNJ63723283, WHO 10757, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center, Janssen Pharmaceutica
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
12/25
12/25
SunRISe-1, NCT04640623 / 2020-002646-16: A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Active, not recruiting
2
220
Europe, Canada, Japan, US, RoW
TAR-200, JNJ-17000139, Gemcitabine-Releasing Intravesical System, Cetrelimab, JNJ-63723283
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
11/26
07/27
QUEST, NCT03431350 / 2017-003552-23: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
1/2
136
Europe, Canada, US, RoW
Niraparib 200 mg, Cetrelimab 240 mg, JNJ-63723283, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg
Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
08/21
12/25
NORSE, NCT03473743 / 2017-001980-19: A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Checkmark Presenation of data from NORSE trial in combination with cetrelimab for 2L metastatic urothelial carcinoma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from NORSE trial in combination with cetrelimab for 2L metastatic urothelial carcinoma at ESMO 2021
Checkmark Presenation of data from NORSE trial in combination with BALVERSA for 2L metastatic urothelial carcinoma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from NORSE trial in combination with BALVERSA for 2L metastatic urothelial carcinoma at ESMO 2021
Active, not recruiting
1/2
125
Europe, US, RoW
Erdafitinib, JNJ-42756493, Cetrelimab, JNJ-63723283, Cisplatin, Carboplatin
Janssen Research & Development, LLC
Urothelial Carcinoma
09/22
12/25
NCT02908906 / 2016-002017-22: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Active, not recruiting
1/2
413
Europe, US, RoW
JNJ-63723283, Cetrelimab
Janssen Research & Development, LLC
Neoplasms
11/23
10/25
PolyDamas, NCT05908734: A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

Recruiting
1/2
75
Europe, US, RoW
Cetrelimab, JNJ-63723283, Amivantamab, JNJ-61186372
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
06/25
09/26
NCT05242445: A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Completed
1
11
Europe
Cetrelimab, JNJ-63723283, Placebo
Janssen Research & Development, LLC
Hepatitis B, Chronic
05/23
05/23
NCT06311578: A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Recruiting
1
96
Europe, US
JNJ-87704916, Cetrelimab, JNJ-63723283
Johnson & Johnson Enterprise Innovation Inc.
Advanced Solid Tumors
11/28
11/33
NCT05818683: A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Recruiting
1
176
Europe, US, RoW
JNJ-78278343, Cetrelimab, JNJ-63723283, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP)
Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Neoplasms
06/26
09/27
ANK-101-004, NCT07027514: A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Not yet recruiting
1
60
NA
tolododekin alfa, Cetrelimab
Ankyra Therapeutics, Inc
Non Small Cell Lung Cancer
06/27
12/28
NCT06116786: A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Recruiting
1
126
Europe, US, RoW
JNJ-86974680, Cetrelimab, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc.
Carcinoma, Non-small-Cell Lung
04/27
06/29
Zynyz (retifanlimab-dlwr) / Incyte
POD1UM-304, NCT04205812 / 2019-003372-39: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Active, not recruiting
3
583
Europe, US, RoW
Retifanlimab, INCMGA00012, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel
Incyte Corporation, Zai Lab (Shanghai) Co., Ltd.
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
12/23
08/26
POD1UM-303, NCT04472429 / 2020-000826-24: Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (/InterAACT 2).

Hourglass Dec 2024 - Dec 2024 : sBLA submission for SCAC
Active, not recruiting
3
308
Europe, Japan, US, RoW
carboplatin, paclitaxel, retifanlimab, INCMGA00012
Incyte Corporation
Squamous Cell Carcinoma of the Anal Canal
04/24
03/26
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
01/26
06/26
2019-004699-21: Study of Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in HER2-Positive Gastric or Gastroesophageal Junction Cancer

Not yet recruiting
2/3
860
Europe, RoW
Margetuximab, INCMGA00012, MGD013, Trastuzumab, MGAH22, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Herceptin
MacroGenics, Inc., MACROGENICS, INC., MacroGenics, Inc., Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator),  Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator), Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator)
Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer, Gastric Cancer or Gastroesophageal Junction Cancer, Diseases [C] - Cancer [C04]
 
 
MAHOGANY, NCT04082364 / 2019-004699-21: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Completed
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
03/25
2021-001181-38: Study on the treatment of patients with gastroesophageal cancer with chemotherapy and immunotherapy based on a non-functioning DNA mismatch repair mechanism in the tumour cells Onderzoek naar de behandeling van patiënten met maag-/slokdarmkanker met chemotherapie en immunotherapie op basis van een niet werkend DNA mismatch herstel mechanisme in de tumorcellen

Not yet recruiting
2
25
Europe
Retifanlimab, INCMGA00012, Solution for infusion
Academic Medical Center, Incyte
Gastroesophageal cancer Oesophagus- en maagcarcinoom, Gastroesophageal cancer Slokdarm- en maagkanker, Diseases [C] - Cancer [C04]
 
 
2020-002244-23: An Open-Label, Randomized, Phase 2, Study of Various Therapies for Participants With Muscle-Invasive bladder cancer who are not eligible for Cisplatin or Refuse Cisplatin Therapy and are having bladder removal (Optimus) Studio generale in aperto, randomizzato, di fase 2 per valutare varie terapie per partecipanti con carcinoma muscolo-invasivo della vescica che sono non idonei al cisplatino o rifiutano la terapia con cisplatino e si sottopongono rimozione della vescica (Optimus)

Not yet recruiting
2
45
Europe
Epacadostat, Retifanlimab, [INCB024360], [INCMGA00012], Tablet, Solution for infusion
INCYTE CORPORATION, Incyte Corporation
Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy Carcinoma uroteliale muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e si sottopone a cistectomia radicale, Muscle-Invasive Bladder cancer Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and having bladder removal Carcinoma muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e con rimozione della vescica, Diseases [C] - Cancer [C04]
 
 
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II.

Not yet recruiting
2
66
Europe
Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide)
Institut Bergonié, Incyte Biosciences International Sarl
retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04]
 
 
2018-002070-51: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Not yet recruiting
2
81
Europe, RoW
INCMGA00012, Solution for infusion
Incyte Corporation, Incyte Corporation
Squamous Carcinoma of the Anal Canal, Squamous Carcinoma of the Anal Canal, Diseases [C] - Cancer [C04]
 
 
POD1UM-201, NCT03599713 / 2018-001627-39: A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma

Checkmark Data from PODIUM-201 trial for metastatic merkel cell carcinoma at SITC 2021
Nov 2021 - Nov 2021: Data from PODIUM-201 trial for metastatic merkel cell carcinoma at SITC 2021
Checkmark Data from POD1UM-201 trial in Merkel cell carcinoma at ESMO 2020
Sep 2020 - Sep 2020: Data from POD1UM-201 trial in Merkel cell carcinoma at ESMO 2020
Completed
2
107
Europe, Canada, US, RoW
Retifanlimab, MGA012, INCMGA00012
Incyte Corporation
Metastatic Merkel Cell Carcinoma
01/22
06/24
2021-005775-39: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Estudio an fase II, aleatorizado, doble ciego y multicéntrico de retifanlimab en combinación con INCAGN02385 e INCAGN02390 como tratamiento de primera línea en participantes con carcinoma escamoso de cabeza y cuello metastásico/recidivante .

Ongoing
2
162
Europe
Retifanlimab, INCMGA00012, INCAGN02385, INCAGN0290, Solution for infusion
Incyte Biosciences International Sarl, Incyte Biosciences International Sarl
In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN. En participantes con PD-L1 positivo y terapia sistémica R/M SCCHN sin tratamiento previo., In participants with biomarker positive and untreated advanced head and neck cancer En participantes con biomarcadores positivos y con cancer de cabeza y cuello avanzado no tratado., Diseases [C] - Cancer [C04]
 
 
NCT04225039: Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

Active, not recruiting
2
39
US
INCMGA00012, PD-1 inhibitor, PD1, INCAGN01876, Anti-GITR agonist, GITR, SRS, stereotactic radiosurgery, Brain surgery
University of Pennsylvania, Incyte Corporation
Glioblastoma
09/22
06/25
2022-000601-27: Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surgery in patients with operable Merkel cell carcinoma Studio volto a testare l’attività di un ciclo di chemio-immunoterapia con retifanlimab associato a platino-etoposide e seguito da chirurgia nei pazienti con carcinoma a cellule di Merkel operabile

Not yet recruiting
2
36
Europe
RETIFANLIMAB, CISPLATINO, carboplatino, etoposide, [INCMGA00012], [CISPLATINO], [carboplatino], [etoposide], Concentrate for solution for infusion
Fondazione GONO, Incyte Biosciences International, Fondazione GONO Onlus
The disease under clinical investigation is represented by resectable Merkel Cell Carcinoma (MCC), stage IIA-III (according to the AJCC staging system 8th edition). The study will include patients with a disease amenable for radical surgery as defined by local or institutional surgical practices, based on multidisciplinary team assessment La malattia oggetto di studio clinico è rappresentata dal tumore a cellule di Merkel (MCC) resecabile, stadiato clinicamente secondo il sistema di stadiazione AJCC, ottava edizione, come stadio IIA-III. Il protocollo arruolerà pazienti candidabili a trattamento chirurgico radicale secondo quanto definito dalla pratica clinica locale ed istituzionale, in seguito a valutazione in ambito multidisciplinare, Merkel cell carcinoma without metastases in other organs and surgically resectable Carcinoma a cellule di Merkel senza metastasi in altri organi e asportabile chirurgicamente, Diseases [C] - Cancer [C04]
 
 
ORPHEUS, NCT04231981 / 2019-001172-11: Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma

Completed
2
18
Europe
Retifanlimab, INCMGA0012
MedSIR, Incyte Biosciences International Sàrl
Penile Cancer
02/22
08/22
IRENE, NCT04445844: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, Study

Checkmark Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Dec 2021 - Dec 2021: Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Active, not recruiting
2
25
US
Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012
Mridula George, MD, Incyte Corporation, Oncolytics Biotech, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
06/25
06/25
NCT04949191 / 2021-002207-36: The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Terminated
2
10
Europe, Japan, US
Pemigatinib, INCB054828, Retifanlimab, INCMGA0012, Pembrolizumab
Incyte Corporation, Incyte Corporation
Advanced Malignancies
04/24
04/24
RHAPSODY, NCT04494009: PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy

Active, not recruiting
2
110
RoW
INCMGA00012
Asan Medical Center
Esophageal Cancer
12/25
12/26
NCT03532295: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Hourglass Jan 2019 - Jan 2019 : P2 trial in recurrent gliomas
Active, not recruiting
2
51
US
Epacadostat, Bevacizumab, Avastin, Radiation therapy, Peripheral blood draw, Retifanlimab, INCMGA00012
Washington University School of Medicine, Incyte Corporation
Glioma, Glioblastoma
07/24
04/26
NCT05359692: INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Withdrawn
2
47
US
INCAGN01876, retifanlimab
Incyte Biosciences International Sàrl
Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
04/24
01/25
Optimus, NCT04586244 / 2020-002244-23: An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Terminated
2
30
Europe, US
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Incyte Corporation, Incyte Corporation
Urothelial Carcinoma
01/24
01/24
NCT05287113: Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
2
176
Europe, Canada, US, RoW
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Incyte Biosciences International Sàrl
Head and Neck Cancer
03/25
06/25
PERELI, NCT06389799: A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma

Recruiting
2
33
Europe
Pemigatinib, Retifanlimab
Lund University Hospital
Dedifferentiated Liposarcoma
12/27
12/28
NCT06160206: Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recruiting
2
134
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
11/26
11/30
MERCURY, NCT05594290: Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery

Recruiting
2
36
Europe
Retifanlimab, Cisplatin, Etoposide
Gruppo Oncologico del Nord-Ovest
Merkel Cell Carcinoma
11/25
11/26
NCT04116073: INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Completed
2
25
US
INCMGA00012 (PD-1 antibody), MGA012
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI)
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
08/24
12/24
RiLEY, NCT05239182: 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Active, not recruiting
2
32
US
9-ING-41, Retifanlimab, INCMGA00012, Gemcitabine, Abraxane
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
12/24
06/25
TORNADO, NCT04968106: Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas

Recruiting
2
66
Europe
Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab
Institut Bergonié, Incyte Biosciences International Sàrl
Resectable Sarcoma
03/25
10/27
POD1UM-204, NCT04463771 / 2020-000496-20: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Active, not recruiting
2
206
Europe, US, RoW
retifanlimab, INCMGA00012, epacadostat, pemigatinib, INCAGN02385, INCAGN02390
Incyte Corporation, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Cancer
04/26
07/26
AuspiCiOus, NCT05177133: Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer

Recruiting
2
25
Europe
Capecitabine, Xeloda, Oxaliplatin, Oxaliplatin Accord, Retifanlimab, INCMGA00012
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Incyte Corporation
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
05/25
11/29
NCT04438824: Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Active, not recruiting
2
42
US
INCMGA00012, Palbociclib
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Well-differentiated/Dedifferentiated Liposarcoma
06/26
06/26
NCT05345002: All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Recruiting
2
55
US
Retifanlimab, All-trans retinoic acid
Stephen Bagley, MD, MSCE, Incyte Corporation, University of Pennsylvania
Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma
06/26
06/27
TRICK-MCC, NCT06056895: Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Active, not recruiting
2
12
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Tuparstobart, Anti-LAG-3 Monoclonal Antibody INCAGN02385, Anti-LAG3 Monoclonal Antibody INCAGN02385, INCAGN 02385, INCAGN 2385, INCAGN02385, INCAGN2385, Verzistobart, Anti-TIM-3 Monoclonal Antibody INCAGN02390, INCAGN 02390, INCAGN-02390, INCAGN02390
University of Washington, Incyte Corporation
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
01/27
04/27
CP-MGC018-01, NCT03729596 / 2018-003555-38: MGC018 With or Without MGA012 in Advanced Solid Tumors

Terminated
1/2
143
Europe, US, RoW
vobramitamab duocarmazine, MGC018
MacroGenics, MacroGenics, Inc.
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer
03/23
03/23
2018-003555-38: Study of MGC018 Alone and in Combination with MGA012 in Patients with Advanced Solid Tumors

Not yet recruiting
1/2
193
Europe
MGC018, MGA012 (INCMGA00012), NA, Concentrate for solution for infusion
MacroGenics, Inc., MacroGenics, Inc.
Advanced Solid Tumors, Advanced cancer disease, Diseases [C] - Cancer [C04]
 
 
NCT06149481: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Recruiting
1/2
60
US
Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682
National Cancer Institute (NCI)
Metastatic Colorectal Cancer
10/25
10/28
NCT06320405: Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Recruiting
1/2
38
US
Axatilimab, Anti-M-CSFR Monoclonal Antibody SNDX-6352, SNDX 6352, SNDX-6352, SNDX6352, UCB6352, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
04/27
04/29
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Anticipated efficiency data in combination with Bria-IMT
Dec 2018 - Dec 2018: Anticipated efficiency data in combination with Bria-IMT
Checkmark Safety data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
11/25
11/28
SANTANA-225, NCT06939036: Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC ( )

Recruiting
1/2
50
US
225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
Ariceum Therapeutics GmbH
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
08/26
12/26
NCT06873789: A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Recruiting
1/2
322
US
INCB177054, Retifanlimab
Incyte Corporation
Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
10/28
10/28
NCT04370704: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Active, not recruiting
1/2
61
US, RoW
INCAGN02385, INCAGN02390, INCMGA00012.
Incyte Corporation
Melanoma
08/25
08/25
NCT04577014: Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Recruiting
1/2
98
US
Retifanlimab, INCMGA00012, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
09/26
09/26
NCT06959537: A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Not yet recruiting
1/2
24
US
Cyclophosphamide, Axatilimab (SNDX-6352), Retifanlimab
M.D. Anderson Cancer Center
Breast Cancer
01/27
01/29
NCT05455697: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Recruiting
1/2
35
US
Bone Marrow Biopsy, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cyclostine, Cytophosphane, Cytoxan, Fosfaseron, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, 14-Hydroxydaunomycin, 23214-92-8, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Prednisone, Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltra, Econosone, Lisacort, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Predicor, Predicorten, Prednicort, Prednilonga, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Retifanlimab, 2226345-85-1, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Tafasitamab, 1422527-84-1, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, 22-Oxovincaleukoblastine, 57-22-7, LEUROCRISTINE, VCR, Vincrystine, Bone Marrow Aspiration, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Fludeoxyglucose F-18, 105851-17-0, 18FDG, Positron Emission Tomography, Medical Imaging, PET Scan, Positron Emission Tomography Scan, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Biospecimen Collection, Biological Sample Collection, Polatuzumab Vedotin, Antibody-Drug Conjugate DCDS4501A, Polivy
University of Washington
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
01/27
07/27
INCMGA 0012-102, NCT03589651: INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Completed
1b
83
US
Retifanlimab, Epacadostat, INCB024360, INCMGA00012, INCB050465
Incyte Corporation
Unresectable or Metastatic Solid Tumors
11/22
11/22
NCT04799431: Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

Withdrawn
1
12
NA
Neoantigen Vaccine with Poly-ICLC adjuvant, Hiltonol® (Poly-ICLC), Retifanlimab, INCMGA00012; MGA012
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI)
Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
05/23
05/23
NCT03522142: A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Active, not recruiting
1
84
Europe, US
INCB081776, INCMGA00012, retifanlimab
Incyte Corporation
Advanced Solid Tumors
09/25
09/25
NCT04470024: Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Recruiting
1
56
US
INCAGN01876, INCMGA00012, DPV-001
Providence Health & Services
Cancer of the Head and Neck
12/25
12/27
NCT06179160: A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting
1
466
Europe, Canada, Japan, US, RoW
INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX
Incyte Corporation
Solid Tumors
01/27
01/27
NCT04580485: INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Completed
1
54
Europe, US
INCB106385, INCMGA00012
Incyte Corporation
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
01/24
01/24
NCT04989387: Study of INCA 0186 in Subjects With Advanced Solid Tumors

Completed
1
57
Europe, US
INCA00186, Retifanlimab, INCB106385
Incyte Corporation
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
09/24
09/24
POD1UM-101, NCT03059823: A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Checkmark Data from PODIUM-101 trial for endometrial cancer at SITC 2021
Nov 2021 - Nov 2021: Data from PODIUM-101 trial for endometrial cancer at SITC 2021
Checkmark First patient dosed in China for 2L MSI-H endometrial cancer
Nov 2020 - Nov 2020: First patient dosed in China for 2L MSI-H endometrial cancer
Checkmark Preliminary data from PODIUM-101 trial for endometrial cancer at SITC 2020
More
Completed
1
325
Europe, US, RoW
retifanlimab, INCMGA0012
Incyte Corporation
Locally Advanced Solid Tumors, Metastatic Solid Tumors
05/24
05/24
NCT06290622: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Withdrawn
1
18
NA
Retifanlimab, INCAGN02385, INCAGN02390
University of Alabama at Birmingham
Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular
06/26
01/28
 

Download Options